Markets:

Overview

News

Currencies

International

Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.010 -0.510 (-6.78%)

Delayed Quote Updated: 3:29 PM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

February 20, 2024

From Arvinas Inc.

Via GlobeNewswire

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

February 14, 2024

From CARRICK THERAPEUTICS LIMITED

Via GlobeNewswire

SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday ↗

February 09, 2024

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results.

Via Benzinga

Topics Stocks

Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High

February 06, 2024

Via Investor Brand Network

Forecasting The Future: 6 Analyst Projections For Arvinas ↗

February 01, 2024

Via Benzinga

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

February 06, 2024

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

February 01, 2024

From Arvinas Inc.

Via GlobeNewswire

Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday ↗

February 01, 2024

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday.

Via Benzinga

Topics Stocks

Expert Outlook: Arvinas Through The Eyes Of 9 Analysts ↗

December 19, 2023

Via Benzinga

Analyst Ratings for Arvinas ↗

November 13, 2023

Via Benzinga

Arvinas Appoints Jared Freedberg as General Counsel

January 16, 2024

Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)

From Arvinas Inc.

Via GlobeNewswire

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 08, 2023

Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.

Via Benzinga

Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday ↗

December 08, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday.

Via Benzinga

Topics Stocks

Analyst Expectations for Arvinas's Future ↗

October 23, 2023

Via Benzinga

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 06, 2023

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 06, 2023

Via Benzinga

THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday ↗

December 06, 2023

U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday.

Via Benzinga

Topics Stocks

Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate ↗

December 06, 2023

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with

Via Benzinga

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

December 05, 2023

From Arvinas Inc.

Via GlobeNewswire

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

December 05, 2023

From Arvinas Inc.

Via GlobeNewswire

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

November 28, 2023

From Arvinas Inc.

Via GlobeNewswire

Why Arvinas (ARVN) Shares Are Seeing Blue Skies ↗

November 27, 2023

Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement.

Via Benzinga

Arvinas Announces Oversubscribed $350 Million Private Placement

November 27, 2023

From Arvinas Inc.

Via GlobeNewswire

Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday ↗

November 14, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter...

Via Benzinga

Topics Stocks

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 07, 2023

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

November 02, 2023

From Arvinas Inc.

Via GlobeNewswire

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

October 22, 2023

From Arvinas Inc.

Via GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

October 18, 2023

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

October 15, 2023

From Arvinas Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.